Neurogenetics acquires global license for using R&D Manage.
October 2001 — NEUROGENETICS, Inc. has subscribed to R&D Manage software and services. Neurogenetics is a San Diego-based emerging biopharmaceutical company focused on the development of therapeutics for Alzheimer's disease (AD) and related neurodegenerative disorders, including Parkinson's disease (PD), Huntington’s disease (HD), stroke, amyotrophic lateral sclerosis (ALS), epilepsy and chronic pain.
PHARMOS Corporation has subscribed to R&D Manage software and services.
October 2001 — PHARMOS Corporation has subscribed to R&D Manage software and services. Additionally, R&D Manage will support consolidation between the Israel and US divisions. Pharmos Corporation is a bio-pharmaceutical company focused on the discovery, development and commercialization of therapeutics for the central and peripheral nervous systems, and ophthalmologic, cardiovascular and inflammation-related indications.
Neurogen (Connecticut) and Pharmos (New Jersey) have selected R&D Manage to support their budgeting and forecasting monthly reporting activities.
October 2001 — NEUROGEN Corporation has acquired a global license for using R&D Manage software and services. Neurogen is a leader in both the discovery and development of new drug candidates and in the development and integration of new drug discovery technologies, most notably its AIDD (Accelerated Intelligent Drug Discovery) system.
HYSEQ and ZYOMYX have selected R&D Manage™ to plan and track their operating expenses.
July 2001 — Hyseq, Inc. and Zyomyx have recently subscribed to R&D Manage software and services. Hyseq, located in Sunnyvale, California, applies its genomics platform to find and develop biopharmaceuticals products. Zyomyx, located in Hayward, California, is developing a new generation of biochips which will enable miniaturized, ultrahigh-throughput protein analyses to bridge the technology gap in the discovery process for the biological and life sciences industry.
10 biotech and pharmaceutical companies are now using our solution for budgeting and forecasting, planning and tracking.
June 2001 — NeoTherapeutics, Inc. and Metabolex, Inc. have recently joined our user community. NeoTherapeutics, located in Irvine, California, is a development-stage biopharmaceutical company engaged in the discovery and advancement of novel therapeutic agents intended to treat neurological and psychiatric diseases and conditions. Metabolex discovers and develops new drugs for type 2 diabetes and brings to market novel drugs with distinct and complementary modes of action, to address the full range of defects underlying diabetes. Both companies will be using R&D Manage on a subscription mode and will first use the system to create their 2002 budgets.
Valentis, Inc. has subscribed to R&D Manage.
March 2001 — Valentis, Inc, is taking the discoveries of genomics research and applying proprietary delivery systems to create therapeutics with improved safety, efficacy or dosing convenience. Valentis has what is believed to be the broadest array of technologies and intellectual property for the delivery of biopharmaceuticals in the industry. R&D Manage will be integrated with Platinum and the local time reporting system. The company has centers in three locations: The Woodlands, Texas, which houses the team focused on preclinical Research & Development; London, England, where PolyMASC operates as a wholly-owned subsidiary and focuses on polymer-based delivery; and Burlingame, California, which is the company headquarters as well as the center for manufacturing and clinical development. R&D Manage will be rolled out to the US locations in April 2001.
Sunesis and Cytokinetics Inc. have also joined our R&D Manage subscription community.
February 2001 — Sunesis Pharmaceuticals is applying a revolutionary new approach to drug discovery that is based on a novel chemical methodology combined with critical insights into the nature of molecular recognition between natural macromolecules and their substrates or ligands. Sunesis will be using R&D Manage™ and the electronic integration with Quick Books. Cytokinetics Inc. is focused on the complementary missions of drug discovery and the commercialization of novel cellular bioinformatics technologies. We are excited to integrate R&D Manage™ with the General Ledger of Microsoft Dynamics accounting system.
Intrabiotics has subscribed to R&D Manage.
February 2001 — Intrabiotics Pharmaceuticals Inc, is a biopharmaceutical company developing novel antibacterial and antifungal drugs for the prevention or treatment of serious infectious diseases, including those related to the phenomenon of multi-drug resistant microbes and the infectious complications of neutropenia. R&D Manage™ will be integrated with MAS90 and local time reporting system.